Comparative Genomic Landscape of Lower-grade Glioma and Glioblastoma
Xinxin Sun, Qingbin Jia, Kun Li, Conghui Tian, Lili Yi, Lili Yan, Juan Zheng, Xiaodong Jia, Mingliang Gu
Abstract
Biomarkers for classifying and grading gliomas have been extensively explored, whereas populations in public databases were mostly Western/European. Based on public databases cannot accurately represent Chinese population. To identify molecular characteristics associated with clinical outcomes of lower-grade glioma (LGG) and glioblastoma (GBM) in the Chinese population, we performed whole-exome sequencing (WES) in 16 LGG and 35 GBM tumor tissues.
Introduction
Gliomas are the most common malignant brain tumors in the central nervous system (CNS). Gliomas are classified into grades I to IV by the World Health Organization (WHO), mainly based on histology and malignancy. Recently, molecular characteristics have been added as an important criterion in the revised classification system. The traditional treatment for glioma includes surgical resection, radiotherapy, and chemotherapy based on temozolomide (TMZ).
Materials and Methods:
Tumor tissues were obtained from 51 patients with primary gliomas from January 6, 2019 to July 1, 2020 in Liaocheng People’s Hospital and normal blood samples data was obtained from another study of our group. These patients were histologically diagnosed with gliomas and underwent surgical resection. According to histopathological diagnosis, tumors were classified as grades II to IV. This study was approved by the medical ethics committee of Liaocheng People’s Hospital (No: 2019203, 6 January 2019) and strictly followed the guidelines of the Declaration of Helsinki.
Discussion:
In this study, we performed WES to compare molecular characteristics between 16 LGG with 35 GBM patients in the Chinese population. We have highlighted significant differences in genetic landscapes between LGG and GBM.
The most frequently mutated genes were TP53, TERT, ATRX, EFGLAM, and IDH1 in 51 Chinese patients with gliomas.
Except for EFGLAM, the other genes were biomarkers for gliomas.
Citation: Sun X, Jia Q, Li K, Tian C, Yi L, Yan L, et al. (2024) Comparative genomic landscape of lower-grade glioma and glioblastoma. PLoS ONE 19(8): e0309536. https://doi.org/10.1371/journal.pone.0309536
Editor: Michael C. Burger, Goethe University Hospital Frankfurt, GERMANY
Received: May 7, 2024; Accepted: August 13, 2024; Published: August 29, 2024.
Copyright: © 2024 Sun et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The data reported in this study are available in the CNGB Nucleotide Sequence Archive (CNSA: https://db.cngb.org/cnsa; accession number CNP0002254 and CNP0002252).
Funding: The author(s) received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
